Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy

BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy using antibodies such as nivolumab or pembrolizumab has shown promise for treating various types of cancer. In this study, we reviewed the frequency and spectrum of cutaneous adverse events (AEs) caused by PD-1 antibodies and their possib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ye Jin, Kim, Hak Tae, Won, Chong Hyun, Chang, Sung Eun, Lee, Mi Woo, Choi, Jee Ho, Lee, Woo Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609422/
https://www.ncbi.nlm.nih.gov/pubmed/31269545
http://dx.doi.org/10.3346/jkms.2019.34.e186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609422/
https://www.ncbi.nlm.nih.gov/pubmed/31269545
http://dx.doi.org/10.3346/jkms.2019.34.e186

Ejemplares similares